Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment

Clinical Journal of Oncology Nursing

Volumn 15, Issue 1, 2011, Pages 88-96

  White, Kathryn J ^a   Roydhouse, Jessica K ^a   Scott, Kathleen ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HOSPITALIZATION; HUMAN; NEOPLASM; PSYCHOLOGICAL ASPECT; REVIEW; SKIN DISEASE;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; SKIN DISEASES;

EID: 79953076975     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/11.CJON.88-96     Document Type: Review

References (74)

1. Agero, A.L., Dusza, S.W., Benvenuto-Andrade, C., Busam, K.J., Myskowski, P., & Halpern, A.C. (2006). Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology, 55, 657-670.
2. Anderson, R., Jatoi, A., Robert, C., Wood, L.S., Keating, K.N., & Lacouture, M.E. (2009). Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist, 14, 291-302. doi: 10.1634/theoncologist.2008-0237
3. Andreis, F., Rizzi, A., Mosconi, P., Braun, C., Rota, L., Meriggi, F., Zaniboni, A. (2010). Quality of life in colon cancer patients with skin side effects: Preliminary results from a monocentric cross sectional study. Health and Quality of Life Outcomes, 8, 40. doi: 10.1186/1477-7525-8-40
4. Au, H., Goldstein, D., Ding, K., Parulekar, W., Gallinger, S., & Moore, M. (2005). Does epidermal growth factor receptor inhibitor skin toxicity affect QOL? Reports from a National Cancer Institute of Canada Clinical Trials Group randomized trial [Abstract 1207]. Quality of Life Research, 14, 2135.
5. Barankin, B., & DeKoven, J. (2002). Psychosocial effect of common skin diseases. Canadian Family Physician, 48, 712-716.
6. Basch, E., Iasonos, A., Barz, A., Culkin, A., Kris, M.G., Artz, D., Schrag, D. (2007). Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. Journal of Clinical Oncology, 25, 5374-5380. doi: 10.1200/JCO.2007.11.2243
7. Basra, M.K., Fenech, R., Gatt, R.M., Salek, M.S., & Finlay, A.Y. (2008). The Dermatology Life Quality Index 1994-2007: A comprehensive review of validation data and clinical results. British Journal of Dermatology, 159, 997-1035.
8. Bauer, K.A., Hammerman, S., Rapoport, B., & Lacouture, M.E. (2008). Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. Clinical Colorectal Cancer, 7, 309-314. doi: 10.3816/CCC.2008.n.040
9. Boone, S.L., Rademaker, A., Liu, D., Pfeiffer, C., Mauro, D.J., & Lacouture, M.E. (2007). Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results. Oncology, 72, 152-159. doi: 10.1159/000112795
10. Both, H., Essink-Bot, M.L., Busschbach, J., & Nijsten, T. (2007). Critical review of generic and dermatology-specific health-related quality of life instruments. Journal of Investigative Dermatology, 127, 2726-2739. doi: 10.1038/sj.jid.5701142
11. Bruner, D. (2007). Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials? Journal of Clinical Oncology, 25, 5345-5347.
12. Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., Hays, R. (2010). The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. Journal of Clinical Epidemiology, 63, 1179-1194. doi: 10.1016/j.jclinepi.2010.04.011
13. Chang, V.T., Hwang, S.S., Feuerman, M., Kasimis, B.S., & Thaler, H.T. (2000). The Memorial Symptom Assessment Scale Short Form (MSAS-SF). Cancer, 89, 1162-1171.
14. Chren, M.M., Lasek, R.J., Quinn, L.M., Mostow, E.N., & Zyzanski, S.J. (1996). Skindex, a quality-of-life measure for patients with skin disease: Reliability, validity, and responsiveness. Journal of Investigative Dermatology, 107, 707-713.
15. Chren, M.M., Lasek, R.J., Sahay, A.P., & Sands, L.P. (2001). Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases. Journal of Cutaneous Medicine and Surgery, 5, 105-110. doi: 10.1007/s102270000010
16. Domino, G., & Domino, M.L. (2006). Psychological testing: An introduction (2nd end.). New York, NY: Cambridge University Press.
17. Dunsford, J. (2008). Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. Clinical Journal of Oncology Nursing, 12, 405-407. doi: 10.1188/08.CJON.405-407
18. Duvic, M. (2008). EGFR inhibitor-associated acneiform folliculitis: Assessment and management. American Journal of Clinical Dermatology, 9, 285-294.
19. Eaby, B., Culkin, A., & Lacouture, M.E. (2008). An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clinical Journal of Oncology Nursing, 12, 283-290. doi: 10.1188/08.CJON.283-290
20. Eilers, R.E., Jr., Gandhi, M., Patel, J.D., Mulcahy, M.F., Agulnik, M., Hensing, T., & Lacouture, M.E. (2010). Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. Journal of the National Cancer Institute, 102, 47-53. doi: 10.1093/jnci/djp439
21. Esper, P., Gale, D., & Muehlbauer, P. (2007). What kind of rash is it? Deciphering the dermatologic toxicities of biologic and targeted therapies. Clinical Journal of Oncology Nursing, 11, 659-666. doi: 10.1188/07.CJON.659-666
22. Gandhi, M., Oishi, K., Zubal, B., & Lacouture, M.E. (2009). Unanticipated toxicities from anticancer therapies: Survivors' perspectives. Supportive Care in Cancer. doi: 10.1007/s00520-009-0769-1
23. Garcia, S.F., Cella, D., Clauser, S.B., Flynn, K.E., Lad, T., Lai, J.S., Weinfurt, K. (2007). Standardizing patient-reported outcomes assessment in cancer clinical trials. Journal of Clinical Oncology, 25, 5106-5112. doi: 10.1200/JCO.2007.12.2341
24. Heidary, N., Naik, H., & Burgin, S. (2008). Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 58, 545-570. doi: 10.1016/j.jaad.2008.01.001
25. Hu, J.C., Sadeghi, P., Pinter-Brown, L.C., Yashar, S., & Chiu, M.W. (2007). Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. Journal of the American Academy of Dermatology, 56, 317-326.
26. Iacovelli, L. (2007). Clinical management of EGFRI-associated dermatologic toxicities: Pharmacy perspective. Oncology (Williston Park), 21(11, Suppl. 5), 31-33.
27. Jatoi, A., & Nguyen, P.L. (2008). Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist, 13, 1201-1204. doi: 10.1634/theoncologist.2008-0149
28. Jatoi, A., Rowland, K., Sloan, J.A., Gross, H.M., Fishkin, P.A., Kahanic, S.P., Loprinzi, C.L. (2008). Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer, 113, 847-853. doi: 10.1002/cncr.23621
29. Jones-Caballero, M., Penas, P.F., Garcia-Diez, A., Badia, X., & Chren, M.M. (2000). The Spanish version of Skindex-29. International Journal of Dermatology, 39, 907-912.
30. Joshi, S., West, D., Witherspoon, J., Lacouture, M., & Ortiz, S. (2009). P1129: Quality of life in patients with epidermal growth factor receptor inhibitor-induced papulopustular rash compared to historically-reported QOL for common dermatologic disorders. Journal of the American Academy of Dermatology, 60(3, Suppl.), AB46.
31. Journagan, S., & Obadiah, J. (2006). An acneiform eruption due to erlotinib: Prognostic implications and management. Journal of the American Academy of Dermatology, 54, 358-360.
32. Kurtin, S.E. (2007). Targeting the epidermal growth factor receptor in colorectal carcinoma. Cancer Nursing, 30(4, Suppl. 1), S1-S9.
33. Lacouture, M.E. (2006). Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews. Cancer, 6, 803-812.
34. Lacouture, M.E. (2007). Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nursing, 30(4, Suppl. 1), S17-S26. doi: 10.1097/01.NCC.0000281758.85704.9b
35. Lacouture, M.E. (2009). The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park), 23, 194-196.
36. Lacouture, M.E. (2010). Sorafenib-induced hand-foot skin reaction treatment [NCT00667589]. Retrieved from http://clinicaltrials.gov/ct2/show/NCT00667589
37. Lacouture, M.E., Cotliar, J., & Mitchell, E.P. (2007). Clinical management of EGFRI dermatologic toxicities: U.S. perspective. Oncology (Williston Park), 21(11, Suppl. 5), 17-21.
38. Lacouture, M.E., & Lai, S.E. (2006). The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. British Journal of Dermatology, 155, 852-854. doi: 10.1111/j.1365-2133.2006.07452.x
39. Lacouture, M.E., Maitland, M.L., Segaert, S., Setser, A., Baran, R., Fox, L.P., Trotti, A. (2010). A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 18, 509-522. doi: 10.1007/s00520-009-0744-x
40. Lacouture, M.E., & Melosky, B.L. (2007). Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: A dermatology-oncology perspective. Skin Therapy Letter, 12(6), 1-5.
41. Lacouture, M.E., Mitchell, E.P., Piperdi, B., Pillai, M.V., Shearer, H., Iannotti, N., Yassine, M. (2010). Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28, 1351-1357. doi: 10.1200/JCO.2008.21.7828
42. Lipworth, A.D., Robert, C., & Zhu, A.X. (2009). Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology, 77, 257-271. doi: 10.1159/000258880
43. Lynch, T.J., Jr., Kim, E.S., Eaby, B., Garey, J., West, D.P., & Lacouture, M.E. (2007). Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist, 12, 610-621. doi: 10.1634/theoncologist.12-5-610
44. Melichar, B., & Nemcova, I. (2007). Eye complications of cetuximab therapy. European Journal of Cancer Care, 16, 439-443. doi: 10.1111/j.1365-2354.2006.00763.x
45. Melosky, B. (2010). Systemic and topical treatments for rash secondary to erlotinib in lung cancer (LUTRAERL) [NCT00473083]. Retrieved from http://clinicaltrials.gov/ct2/show/NCT00473083
46. Meriggi, F., Rizzi, A., Andreis, F., Rota, L., Mazzocchi, M., Di Biasi, B., Zaniboni, A. (2008). Skindex-29 (SD-29) for health-related quality of life (HRQoL) assessment during antiEGFr therapies for colorectal cancer (CRC) [Abstract 20721]. Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32551
47. Molinari, E., De Quatrebarbes, J., Andre, T., & Aractingi, S. (2005). Cetuximab-induced acne. Dermatology, 211, 330-333.
48. Morse, L., & Calarese, P. (2006). EGFR-targeted therapy and related skin toxicity. Seminars in Oncology Nursing, 22, 152-162. doi: 10.1016/j.soncn.2006.04.005
49. National Cancer Institute Cancer Therapy Evaluation Program. (1999). Common Toxicity Criteria [v2.0]. Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
50. National Cancer Institute Cancer Therapy Evaluation Program. (2006). Common Terminology Criteria for Adverse Events [v3.0]. Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
51. National Cancer Institute Cancer Therapy Evaluation Program. (2010). Common Terminology Criteria for Adverse Events and Common Toxicity Criteria [v4.0]. Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_v40
52. Nijsten, T.E., Sampogna, F., Chren, M.M., & Abeni, D.D. (2006). Testing and reducing Skindex-29 using Rasch analysis: Skindex-17. Journal of Investigative Dermatology, 126, 1244-1250. doi: 10.1038/sj.jid.5700212
53. Nunnally, J.C. (1978). Psychometric theory (2nd ed.). New York, NY: McGraw-Hill.
54. Oishi, K. (2008). Clinical approaches to minimize rash associated with EGFR inhibitors. Oncology Nursing Forum, 35, 103-111. doi: 10.1188/08.ONF.103-111
55. Osio, A., Mateus, C., Soria, J.C., Massard, C., Malka, D., Boige, V., Robert, C. (2009). Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. British Journal of Dermatology, 161, 515-521.
56. Peeters, M., Siena, S., Van Cutsem, E., Sobrero, A., Hendlisz, A., Cascinu, S., Amado, R.G. (2009). Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer, 115, 1544-1554. doi: 10.1002/cncr.24088
57. Perez-Soler, R. (2007). Erlotinib: Recent clinical results and ongoing studies in non-small cell lung cancer. Clinical Cancer Research, 13(15, Pt. 2), S4589-S4592. doi: 10.1158/1078-0432.CCR-07-0541
58. Perez-Soler, R., & Van Cutsem, E. (2007). Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology (Williston Park), 21(11, Suppl. 5), 10-16.
59. Portenoy, R.K., Thaler, H.T., Kornblith, A.B., Lepore, J.M., Friedlander-Klar, H., Kiyasu, E., Norton, L. (1994). The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. European Journal of Cancer, 30A, 1326-1336.
60. Purdom, M., & Ohinata, A. (2007). Clinical management of EGFRI dermatologic toxicities: The nursing perspective. Oncology (Williston Park), 21(11, Suppl. 5), 29-30.
61. Robert, C., Soria, J.C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., Le Chevalier, T. (2005). Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncology, 6, 491-500.
62. Romito, F., Giuliani, F., Cormio, C., Tulipani, C., Mattioli, V., & Colucci, G. (2010). Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Supportive Care in Cancer, 18, 329-334. doi: 10.1007/s00520-009-0656-9
63. Saif, M.W., Kaley, K., Lamb, L., Pecerillo, J., Hotchkiss, S., Steven, L., Shaib, W. (2010). Management of skin toxicities of anti-EGFR agents in patients with pancreatic cancer and other GI tumors by using electronic communication: Effective and convenient. Journal of the Pancreas, 11, 176-182.
64. Saif, M.W., Merikas, I., Tsimboukis, S., & Syrigos, K. (2008). Erlotinib-induced skin rash. Pathogenesis, clinical significance, and management in pancreatic cancer patients. Journal of the Pancreas, 9, 267-274.
65. Scope, A., Agero, A.L., Dusza, S.W., Myskowski, P.L., Lieb, J.A., Saltz, L., Halpern, A.C. (2007). Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. Journal of Clinical Oncology, 25, 5390-5396. doi: 10.1200/JCO.2007.12.6987
66. Scope, A., Lieb, J.A., Dusza, S.W., Phelan, D.L., Myskowski, P.L., Saltz, L., & Halpern, A.C. (2009). A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. Journal of the American Academy of Dermatology, 61, 614-620.
67. Segaert, S., & Van Cutsem, E. (2005). Clinical signs, pathophysiology, and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology, 16, 1425-1433. doi: 10.1093/annonc/mdi279
68. Segaert, S., & Van Cutsem, E. (2007). Clinical management of EGFRI dermatologic toxicities: The European perspective. Oncology (Williston Park), 21(11, Suppl. 5), 22-26.
69. Sloan, J.A., Berk, L., Roscoe, J., Fisch, M.J., Shaw, E.G., Wyatt, G., National Cancer Institute. (2007). Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. Journal of Clinical Oncology, 25, 5070-5077. doi: 10.1200/JCO.2007.12.7670
70. Tsimboukis, S., Merikas, I., Karapanagiotou, E.M., Saif, M.W., & Syrigos, K.N. (2009). Erlotinib-induced skin rash in patients with non-small cell lung cancer: Pathogenesis, clinical significance, and management. Clinical Lung Cancer, 10, 106-111. doi: 10.3816/CLC.2009.n.013
71. U.S. Food and Drug Administration. (2009). Guidance for industry: Patient-reported outcomes measure: Use in medical product development to support labeling claims. Retrieved from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
72. Wagner, L., Lai, S.E., Aneja, M., Lorusso, P., Perez-Soler, R., O'Brien, B., Lacouture, E. (2007). Development of a functional assessment of side effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI [Abstract 19532]. Retrieved from http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/19532
73. Wagner, L.I., & Lacouture, M.E. (2007). Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park), 21(11, Suppl. 5), 34-36.
74. Witherspoon, J.N., Wagner, L., Rademaker, A., West, D.P., Rosenbaum, S.E., & Lacouture, M.E. (2008). Correlation of patient characteristics and NCI-common terminology criteria for adverse events (CTCAE) v3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash [Abstract 9559]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detailview&confID=55&abstractID=35365